Posted by Michael Wonder on 31 Oct 2016
TGA approves new combination product for type 2 diabetes
31 October 2016 - The TGA has approved AstraZeneca's Qtern (saxagliptin hydrochloride with dapagliflozin propanediol monohydrate).
Qtern 5/10 is indicated as an adjunct to diet and exercise, in combination with metformin, to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and dapagliflozin is appropriate.
Qtern was approved by the TGA on 25 October 2016.
